Mark O’Mahony
Corporate Officer/Principal bei LEAP THERAPEUTICS, INC.
Vermögen: 15 850 $ am 30.04.2024
Profil
Mark O’Mahony is currently the Chief Manufacturing Officer at Leap Therapeutics, Inc. He previously worked as a Principal at Millennium Pharmaceuticals, Inc. and LeukoSite, Inc. He also served as the VP-Process Development & Manufacturing at Tolerx, Inc. Mr. O’Mahony has an MBA from Boston University and an undergraduate degree from University College Dublin.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LEAP THERAPEUTICS, INC.
0,02% | 29.01.2024 | 5 000 ( 0,02% ) | 15 850 $ | 30.04.2024 |
Aktive Positionen von Mark O’Mahony
| Unternehmen | Position | Beginn |
|---|---|---|
| LEAP THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2011 |
Ehemalige bekannte Positionen von Mark O’Mahony
| Unternehmen | Position | Ende |
|---|---|---|
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 19.12.2011 |
LeukoSite, Inc.
 LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Corporate Officer/Principal | 01.01.2000 |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.01.2000 |
DecImmune Therapeutics, Inc.
 DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Corporate Officer/Principal | - |
| Serono Corp. | Corporate Officer/Principal | - |
Ausbildung von Mark O’Mahony
| Boston University | Masters Business Admin |
| University College Dublin | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LEAP THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
| Serono Corp. |
